<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888677</url>
  </required_header>
  <id_info>
    <org_study_id>SBG 2000-1</org_study_id>
    <nct_id>NCT03888677</nct_id>
  </id_info>
  <brief_title>Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer</brief_title>
  <official_title>SBG 2000-1. Individually Dose-adjusted FEC Compared to Standard FEC as Adjuvant Chemotherapy for Node Positive or High-risk Node Negative Breast Cancer. A Randomized Study by the Scandinavian Breast Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Lindman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scandinavian Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacia Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open randomized phase III study. The primary objective of this study is to compare
      FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated
      according to the patients surface area or with doses adjusted according to leukopenia after
      course one in order to achieve hematological equitoxicity. The main aim of the study is to
      test whether chemotherapy dosage aimed at hematological equitoxicity will improve the effect
      of adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group A, FECStandard(standard FEC) is given 7 courses of 5-fluorouracil-epirubicin
      (Farmorubicin)-cyclophosphamide with doses based on the patient's surface area. Leukocyte
      nadir values at day 10, 12 or 13 and 15 are measured. Dose-reductions of one step according
      to table 8.2.1 are performed in case of leukopenic fever or grade 4 leukopenia.

      Group B FECTailored(Tailored FEC) receives course one at identical doses to group A.
      Leukocyte nadir values at day 10,12 or 13 and 15 are measured. Doses of subsequent courses
      are adjusted to achieve grade 3 leukopenia (leukocyte nadir 1.0 to 2.0) in patients
      experiencing only grade 0 to 2 leukopenia after course one.

      Dose-reductions of one step according to table 8.2.1 are performed in case of leukopenic
      fever or grade 4 leukopenia .

      Patients achieving only grade 0-2 leukopenia at the first course will be randomized into
      continued treatment at standard doses (Group A) or to doses tailored to achieve grade 3
      leukopenia (Group B). The primary comparisons will be made between these two groups of
      patients.

      Patients with grade 3-4 leukopenia after the first course not be randomized but followed
      according to the protocol and received treatment as group A, FECStandard.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2001</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distant disease-free survival.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Distant disease-free survival comparing standard and tailored arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regio-locally relapsed disease</measure>
    <time_frame>5-10 years</time_frame>
    <description>Regiolocal disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-10 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of treatment.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukopenia and correlation to prognosis in distant disease-free survival.</measure>
    <time_frame>5-10 years.</time_frame>
    <description>Distant disease-free survival in patients groups based on nadir leukopenia after third cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of dose escalation of leukopenia and correlation to prognosis in distant disease-free survival.</measure>
    <time_frame>5-10 years.</time_frame>
    <description>Comparing distant disease-free survival difference between patients randomized to tailored and dose-escalated FEC with the Group of patients with standard FEC but with similar grade of leukopenia.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1535</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard FEC (F600, E60, C600) every 3rd week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tailored</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored FEC (F600, E75-90, C900-1200) every 3rd week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Registered</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU, epirubicin and cyclophosphamide</intervention_name>
    <description>Tailored dose escalation of epirubicin and cyclophosphamide.</description>
    <arm_group_label>Registered</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_label>Tailored</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Node positive or 2) High-risk node negative#

          -  no major cardiovascular morbidity

          -  female age 18-60

          -  ECOG/WHO performance status &lt;1

          -  histologically proven invasive breast cancer

          -  written or oral witnessed informed consent according to the local Ethics Committee
             requirements

          -  start of adjuvant chemotherapy within 8 weeks after surgery

        Exclusion Criteria:

          -  distant metastases (M1)

          -  locally advanced cancer

          -  nonradically operated (positive resection margins)

          -  pregnancy or lactation

          -  leukocyte count &lt; 3.5 x109 /l

          -  platelets &lt; 100 x109 /l

          -  other serious medical condition

          -  previous or concurrent malignancies at other sites, except basal cell carcinoma and
             carcinoma cervicis uteri in situ
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Lindman</investigator_full_name>
    <investigator_title>Senior Consultant, Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing with EBCTCG (Early Breast Cancer Trialists' Collaborative Group).</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After 5 years.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

